Pre-existence and persistence of resistant minority hepatitis C virus variants in genotype 1-infected patients treated with simeprevir/peginterferon/ribavirin

Open Forum Infectious Diseases

Volumn 3, Issue 2, 2016, Pages

  Fevery, Bart ^a   Thys, Kim ^a   Van Eygen, Veerle ^a   Verbinnen, Thierry ^a   Van Rossem, Elizabeth ^a   Buelens, Annemie ^a   Aerssens, Jeroen ^a   Witek, James ^b   Picchio, Gaston ^b   De Meyer, Sandra ^a   Lenz, Oliver ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Deep sequencing; HCV; Minority (viral) variants; Resistance; Simeprevir

Indexed keywords

PEGINTERFERON; RIBAVIRIN; SIMEPREVIR;

ARTICLE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; REPLICON; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS;

EID: 84995663202     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofw052     Document Type: Article

References (17)

1. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146:1669-79
2. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naîve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58:1918-29
3. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebocontrolled trial. Lancet 2014; 384:403-13
4. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384:414-26
5. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146:430-41
6. Lenz O, Verbinnen T, Lin TI, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54:1878-87
7. Lenz O, Verbinnen T, Fevery B, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol 2015; 62:1008-14
8. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008; 26:1135-45
9. Thys K, Verhasselt P, Reumers J, et al. Performance assessment of the Illumina massively parallel sequencing platform for deep sequencing analysis of viral minority variants. J Virol Methods 2015; 221:29-38
10. Vandenbroucke I, van Marck H, Verhasselt P, et al. Minor variant detection in amplicons using 454 massive parallel pyrosequencing: experiences and considerations for successful applications. Biotechniques 2011; 51:167-77
11. Verbinnen T, Fevery B, Vijgen L, et al. In vitro activity of simeprevir against hepatitis C virus genotype-1 clinical isolates and its correlation with NS3 sequence and site-directed mutants. Antimicrob Agents Chemother 2015; 59:7548-57
12. Dierynck I, Thys K, Ghys A, et al. Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study. J Infect Dis 2014; 210:1871-80
13. Fonseca-Coronado S, Escobar-Gutiérrez A, Ruiz-Tovar K, et al. Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naïve infected individuals. J Clin Microbiol 2012; 50:281-7
14. Nasu A, Marusawa H, Ueda Y, et al. Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS One 2011; 6:e24907
15. Dvory-Sobol H, Doehle B, Svarovskaia E, et al. The prevalence of HCV NS5A, nucleoside and protease inhibitor resistance associated variants and the effects on treatment with ledipasvir/sofosbuvir±RBV in the Phase 3 ION studies. International Workshop on Antiviral Drug Resistance, Berlin, Germany, June 3-11, 2014. (Poster)
16. Ogert RA, Howe JA, Vierling JM, et al. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-a2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial. Antivir Ther 2013; 18:387-97
17. Svarovskaia ES, Martin R, McHutchison JG, et al. Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy. J Clin Microbiol 2012; 50:3267-74